Boundless Bio, a precision oncology company, is focused on developing therapies for cancers with oncogene amplifications, specifically targeting extrachromosomal DNA (ecDNA). The company, co-founded by Dr. Paul Mischel, is advancing a pipeline of ecDNA-directed therapies, aiming to provide novel treatments for cancers that currently have limited options. Boundless Bio has received significant recognition and funding for its innovative approach to cancer treatment, highlighting its role in the field of oncogene amplified cancers.